Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hims & Hers Health Inc
(NY:
HIMS
)
16.10
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
29,428
Open
16.10
Bid (Size)
16.05 (100)
Ask (Size)
16.10 (9)
Prev. Close
16.10
Today's Range
16.10 - 16.10
52wk Range
5.650 - 25.74
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Hims & Hers Acquisition: How Innovation Will Flourish
Today 5:00 EDT
Buying a new pharmacy will allow Hims & Hers to expand into new markets.
Via
The Motley Fool
How Is The Market Feeling About Hims & Hers Health?
September 17, 2024
Via
Benzinga
Performance
YTD
+67.01%
+67.01%
1 Month
-2.78%
-2.78%
3 Month
-35.05%
-35.05%
6 Month
+2.94%
+2.94%
1 Year
+153.94%
+153.94%
More News
Read More
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Via
The Motley Fool
Hims & Hers Stock Pops After Massive Acquisition
September 13, 2024
Via
The Motley Fool
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)
September 13, 2024
Via
Benzinga
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
September 11, 2024
Via
The Motley Fool
Is Hims & Hers Health Stock a Buy?
September 10, 2024
Via
The Motley Fool
Is Hims & Hers Health Stock a Buy?
August 29, 2024
Via
The Motley Fool
What Is Going On With Hims & Hers Stock?
August 22, 2024
Via
The Motley Fool
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
Via
The Motley Fool
Exposures
COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
September 11, 2024
Via
Benzinga
Exposures
Product Safety
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
September 10, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Four Stocks To Watch This Week - Monday, Sept 9
September 09, 2024
Via
Talk Markets
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
September 05, 2024
Via
Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
September 05, 2024
Via
The Motley Fool
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
September 05, 2024
Via
The Motley Fool
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
September 01, 2024
Via
The Motley Fool
2 No-Brainer Growth Stocks to Buy With $200 Right Now
August 31, 2024
Via
The Motley Fool
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Why Hims & Hers Health Stock Was Falling This Week
August 29, 2024
Via
The Motley Fool
Why Hims & Hers Stock Crashed on Tuesday
August 27, 2024
Via
The Motley Fool
Why Hims & Hers Health Stock Is Falling
August 27, 2024
Via
Benzinga
American Woodmark Reports Downbeat Results, Joins Snowflake And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
August 27, 2024
Via
Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
August 27, 2024
Via
Investor's Business Daily
Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst
August 22, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.